SymBio Pharmaceuticals Inc.
Basic information
- Head office
- 7th Floor, Toranomon Towers Office, 1-28 Toranomon 4-chome, Minato-ku, Tokyo 105-0001, Japan
- Chief executive
- Fumiki Yoshida
- Capital
- 19,244,128,000 (192 100 million)
- Employees (non-consolidated)
- 101 people
- Employees (consolidated)
- Start date
- 2005-03-25
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
Network
History
License Agreement finalized with Astellas Pharma GmbH for SyB L-0501 (bendamustine) development & commercialization rights in Japan![]()
Entered into a license agreement with Astel Pharma (Germany) for exclusive development and sale of the anticancer agent 'Bendamustine Hydrochloride' in Japan.![]()
Manufacturer's License (packaging, labeling and storage) obtained from Tokyo Metropolitan Government![]()
Obtained a permit from the Tokyo Metropolitan Government for pharmaceutical manufacturing (packaging, labeling, storage) (Permit No.: 13AZ200010).![]()
License Agreement finalized with Astellas Deutschland GmbH for SyB L-0501 (bendamustine) development & commercialization rights in China (HK), Taiwan, Korea and Singapore![]()
Entered into a license agreement with Astel Dichtlants (Germany) for exclusive development and sale of the anticancer agent 'SyB L-0501' in China, Korea, Taiwan, and Singapore.![]()
License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in Japan![]()
SymBio Pharmaceuticals concludes Sublicense Agreement with Cephalon, Inc. for development and commercialization rights of bendamustine hydrochloride in China (HK)![]()
Entered into a sublicense agreement with Cefalon Inc. (USA) granting development and commercialization rights for the anticancer agent 'SyB L-0501' in China.![]()
License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in Korea and Singapore![]()
Entered into a license agreement with Eisai Co., Ltd. for the anticancer agent 'SyB L-0501' targeting Korea and Singapore.![]()
Entered into a license agreement with Oncova Inc. (USA) regarding the anticancer agents 'SyB L-1101/SyB C-1101'.![]()
Approval for Domestic Manufacturing and Marketing of Anticancer Agent TREAKISYM for Additional Indication of Chronic Lymphocytic Leukemia![]()
Obtained domestic manufacturing and sales approval for the additional efficacy of the anticancer agent 'TREAKISYM : ® :' against chronic lymphocytic leukemia.![]()
SymBio Pharmaceuticals announces the NDA approval of TREAKISYM (bendamustine) for the additional indication of First-line Treatment of Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma in Japan![]()
Obtained domestic manufacturing and sales approval for the additional efficacy of the anticancer agent Treaxin® for untreated low-grade non-Hodgkin lymphoma and mantle cell lymphoma.![]()
Eagle Pharmaceuticals (NASDAQ: EGRX) and SymBio Pharmaceuticals completed License Agreement for bendamustine liquid formulations (RTD Injection and RI Injection) development & commercialization rights in Japan *RTD: Ready-to-dilute, RI: Rapid Infusion![]()
Entered an exclusive licensing agreement with Eagle Pharmaceuticals (USA) for the development and commercialization of Bendamustine liquid formulations (RTD and RI) in Japan.![]()
TREAKISYM (bendamustine) has been newly included as a standard-of-care option in the Guidelines for Tumors of Hematopoietic and Lymphoid Tissues 2018![]()
Treaxin® was newly included as a standard treatment option in the 2018 edition of the Hematologic Tumor Treatment Guidelines.![]()
Treaxin® was newly included as a standard treatment option in the 2018 edition of the Hematologic Tumor Treatment Guidelines.![]()
September 2019: Chimerix (USA) and anti-viral drug 'Brinshidohobiru' (excluding smallpox) entered into an exclusive global license agreement for development, sales, and manufacturing![]()
Entered an exclusive global licensing agreement with Chimerix (USA) for the development, sale, and manufacture of the antiviral drug Brinshidobiv (excluding smallpox).![]()
SymBio Pharmaceuticals receives approval of TREAKISYM : ® : (bendamustine) in combination with rituximab, and in combination with rituximab and polatuzumab vedotin for relapsed or refractory diffuse large B-cell lymphoma![]()
Obtained approval for the combination therapy of Treaxin® and rituximab for relapsed or refractory diffuse large B-cell lymphoma, and also approval for the combination therapy of Treaxin®, rituximab, and polatuzumab vedotin.![]()
SymBio Pharmaceuticals receives approval of TREAKISYM : ® : Ready-To-Dilute (RTD) Formulation in combination with rituximab ,and in combination with rituximab and polatuzumab vedotin for relapsed or refractory diffuse large B-cell lymphoma![]()
Obtained approval for the combination therapy of Treaxin® liquid formulation (RTD) and rituximab for relapsed or refractory diffuse large B-cell lymphoma, and also approval for the combination therapy of Treaxin® liquid formulation (RTD), rituximab, and polatuzumab vedotin.![]()
News
There is no news.
Public records
National Tax Agency basic information1010401057034
- Trade name
- シンバイオ製薬株式会社
- Trade name (kana)
- シンバイオセイヤク
- Name in English
- Corporation type
- 301
- Address
- 〒105-0001 東京都港区虎ノ門4丁目1番28号
- Postal code
- 1050001
- Prefecture code
- 13
- City code
- 103
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-10-05
- Update date
- 2023-12-04
- Change date
- 2023-12-01
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 12
- Correction type
- 0
- Trade name image ID
- Address image ID
- Sequence number
- 1298574
METI gBizINFO1010401057034
- Corporate number
- 1010401057034
- Trade name
- シンバイオ製薬株式会社
- Trade name (kana)
- シンバイオセイヤク
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 東京都港区虎ノ門4丁目1番28号
- Postal code
- 1050001
- Prefecture
- 東京都
- Prefecture code
- 13
- City or district
- 港区
- City code
- 103
- Street address
- 虎ノ門4丁目1番28号
- Organisation type
- 301
- Processing type
- 12
- Correction type
- 0
- Status
- Representative
- 代表取締役社長兼CEO 吉田 文紀
- Capital
- 19244128000
- Employees
- 150
- Employees (male)
- Employees (female)
- Business summary
- Website URL
- Year founded
- Business category
- E:製造業
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2023-12-04
- Key information
- 1010401057034